Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00derived−100.0% vs Q3 2022 Net Income-$3.22M-$3.22MN/M vs Q3 2022 EPS Diluted-$0.08-$0.08N/M vs Q3 2022 Operating Income-$2,893,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
Operating Cash Flowderived-$694,000N/M Free Cash Flowderived-$726,000N/M ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end